1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cancer Drug News 02 FEBRUARY 2015

Cancer Drug News 02 FEBRUARY 2015

  • February 2015
  • -
  • Espicom Business Intelligence
  • -
  • 20 pages

Industry Trend Analysis - OncoMed's Latest ODD Highlights Anti-CSC Potential
Industry Brief - DSMB Recommends Continuation of Masitinib Phase II Study In Relapsed BC
Industry Trend Analysis - Amgen's Filings For Kyprolis In MM Will Not Affect Celgene's Product Sales
Industry Brief - MacroGenics/Janssen Close MGD011 Licensing Deal For Multiple B-Cell Malignancies
Industry Brief - OSE Pharma/Simbec-Orion Begin Tedopi Phase III Trial In HLA-A2+ NSCLC
Industry Brief - FDA Grants Breakthrough Therapy Designation To Genentech's Anti-PDL1 Immunotherapy
Industry Brief - Eisai's Lenvatinib Phase II Trial Meets Primary Endpoint In MRCC
Industry Brief - Hexvix Significantly Improves OS/RFS In Bladder Cancer
Industry Brief - Insys' Liposomal Encapsulated Paclitaxel Gains FDA ODD For Ovarian Cancer
Industry Brief - Advaxis' ADXS-HPV Phase II CC Study Achieves Safety/Efficacy Criteria
Industry Brief - First Patient Dosed In Dicerna's DCR-MYC Phase Ib/II Trial For Advanced HCC
Industry Brief - Stemline's SL-701 Gains FDA Orphan Drug Designation For Glioma
Industry Trend Analysis - J&J's Investment Will Secure Oncology Segment's Growth
Industry Brief - Symphogen Regains Rights To Sym004 From Merck; Makes Organisational Changes
Industry Trend Analysis - Precision Medicine Initiative Promotes Data-Driven Treatment
Industry Brief - MediciNova Secures Japanese Patent Covering MN-029
Industry Brief - BDSI Acquires North American Marketing Authorisations For Onsolis From Meda
Industry Brief - GSK Extends Price Freeze Commitment For Gavi-Eligible Countries
Industry Brief - Oncolix Raises Funds For Prolanta Phase I OC Trial
Industry Trend Analysis - Valeant Uses Cheap Acquisition To Enter Cancer Market
Industry Brief - Incanthera Raises Funds For Acquisition Of Drug Programme/Spear Therapeutics
Industry Brief - Cancer Conferences - May 2015

Table Of Contents

Cancer Drug News 02 FEBRUARY 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.